AstraZeneca PLC — Director's Dealing 2025

May 1, 2025

National Storage Mechanism | Additional information

RNS Number : 1142H

AstraZeneca PLC

01 May 2025

1 May 2025

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announces that it was notified on 1 May 2025 that Karen Knudsen, Non-Executive Director, purchased 1,400 of the Company's American Depositary Shares (ADSs) on 30 April 2025 , as set out below. Two ADSs are equivalent to one of the Company's ordinary shares of $0.25 each .

PDMR	Position	Nature of the transaction	Quantity	Price per ADS
Karen Knudsen	N on-Executive Director	Purchase of A DSs	1,400	$71.655

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (since it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Karen Knudsen

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

AstraZeneca PLC

b)

LEI

PY6ZZQWO2IZFZC3IOL08

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

AstraZeneca PLC American Depositary Shares

CUSIP: 046353108

b)

Nature of the transaction

Purchase of AstraZeneca PLC American Depositary Shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
$71.655	1,400

d)

Aggregated information

- Aggregated volume

- Price

Not applicable - single transaction

e)

Date of the transaction

30 April 2025

f)

Place of the transaction

XNAS

AstraZeneca  

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit  astrazeneca.com  and follow the Company on social media  @AstraZeneca  

Contacts

For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

Matthew Bowden

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUAOORVWUVRAR